© 2022 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
November 09, 2012
A substudy of the PLATO trial reveals that treatment with ticagrelor reduces cardiovascular death, myocardial infarction, and stroke in some patients with non-ST-elevation acute coronary syndrome.
Results from the RELAX-AHF show serelaxin reduces cardiovascular deaths and improves symptoms in patients with heart failure.
Results from a substudy of the PLATO trial show that patients with extensive CAD and high rates of recurrent cardiovascular events, death, and bleeding may benefit from treatment with ticagrelor.
November 08, 2012
Study results presented at the American Heart Association 2012 Scientific Sessions show that visible signs of aging such as baldness and yellow fatty deposits around the eye are predictors for heart attack and heart disease risk.
Can Glasses Help Prevent COVID-19? Data Remain Unsure
Autonomous AI-based System Compliant with Expert Consensus for AMD Treatment
Simulation Software Could Improve Teenage ADHD Driver Safety